[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367076-105":59,"doc-detail-367076-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ck2-mediated-phosphorylation-of-dub3-promotes-yap1-stability-and-oncogenic-functions-article","CK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions - Article","","Aberrant upregulation of Yes-associated protein 1 (YAP1) drives tumor progression and worsens clinical outcomes in many solid cancers, yet direct YAP1-targeted therapies remain difficult. High-throughput screening identifies Casein kinase II (CK2) as an upstream regulator of YAP1 turnover. Pharmacologic CK2 inhibition (Silmitasertib) or genetic depletion of CK2α destabilizes YAP1 and suppresses oncogenic functions in vitro and in vivo. The study connects CK2α to DUB3-mediated deubiquitination of YAP1 via Thr495 phosphorylation, with CK2α and DUB3 levels correlating with YAP1 overexpression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ck2-mediated-phosphorylation-of-dub3-promotes-yap1-stability-and-oncogenic-functions-article/367076/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ck2-mediated-phosphorylation-of-dub3-promotes-yap1-stability-and-oncogenic-functions-article/367076.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is YAP1 considered an appealing therapeutic target?","Question",{"text":112,"@type":113},"YAP1 is frequently upregulated in solid cancers and contributes to tumor progression, drug resistance, metastasis, and poor survival outcomes, making it a desirable target for therapy development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CK2α affect YAP1 in this study?",{"text":117,"@type":113},"CK2α functions upstream to regulate YAP1 turnover. Inhibiting CK2α or depleting its catalytic subunit destabilizes YAP1 and suppresses oncogenic functions in vitro and in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does DUB3 play in the CK2α–YAP1 pathway?",{"text":121,"@type":113},"DUB3 is identified as a deubiquitinase of YAP1 and functionally links CK2 to YAP1 stability. CK2α directly phosphorylates DUB3 at Thr495 to facilitate DUB3-mediated deubiquitination of YAP1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367076,1790887976,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nCK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions  \nLei Huang 1,9, Yalei Wen2,9, Qin Guo3,9, Caishi Zhang4,9, Xiao Yang 1, Mei Li1, YiXia Liu1, Xinying Li1, Jiaxin Tang5,6, Xiaofeng Zhou 7  \nQi Qi 7 ✉, Haoxing Zhang 6 ✉ and Tongzheng Liu 1,8 ✉ ,  \n© The Author(s) 2025  \n\n| | The aberrant upregulation of Yes-associated protein 1 (YAP1) in a variety of solid cancers contributes to tumor progression and poor clinical outcomes, rendering it an appealing therapeutic target. However, effective therapies to directly target YAP1 remain challenging. In this study, we perform a high-throughput screening and identify Casein kinase II (CK2) as an uncharacterized upstream regulator of YAP1 turnover in cancer cells of ovarian cancer and several other cancer types. Pharmacological inhibition of Casein kinase II by Silmitasertib or genetic depletion of the catalytic subunit of Casein kinase II (CK2α) markedly destabilizes YAP1 and consequently suppresses its oncogenic functions in vitro and in vivo. Moreover, we reveal that DUB3 as a bona ﬁdedeubiquitinase of YAP1, which functionally links CK2 and YAP1 stability in a variety of human cancers. Mechanistically, CK2α directly phosphorylates DUB3 at Thr495, thereby facilitating DUB3-mediated deubiquitination process of YAP1 . On the contrary, the loss of Thr495 phosphorylation by the phosphorylation-defective mutant DUB3 T495A, the cancer-related mutant DUB3 D496H and CK2 inhibition failed to deubiquitinate and stabilize YAP1 effectively. Notably, upregulated expressions of CK2α and DUB3 in ovarian cancer positively correlate with YAP1 overexpression. Collectively, our ﬁndings demonstrate the functional signiﬁcance of the CK2α-DUB3 axis in YAP1 stabilization and YAP1-driven tumor progression, highlighting that strategies to target this axis might be of beneﬁt in the clinical management of ovarian cancer and several other lethal cancers with aberrantly | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | upregulated YAP1 . |  |\n|  |  |  |\n|  |  |  |\n|  | Cell Death and Disease (2025)16:27; [https://doi.org/10.1038/s41419-024-07323-z](https://doi.org/10.1038/s41419-024-07323-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nOvarian cancer is the deadliest gynecologic malignancy worldwide with limited effective therapies [1] . Cisplatin and other conventional chemotherapies remain standard treatments for ovarian cancer [2] . However, chemo-resistance frequently occurs and causes treatment failure in ovarian cancer [3] . Thus, identifying novel therapeutic targets and developing new strategies are urgently needed for the clinical management of ovarian cancer.  \nYes-associated protein 1 (YAP1) is the key effector of the Hippo suppressive pathway which is pivotal in the regulation of tissue regeneration, organ development and cell proliferation [4, 5] . When the Hippo pathway is inhibited or the core kinase cascades MST/MAP4K/LATS are dysregulated, hypophosphorylated YAP1 translocated to the nucleus and interacts with transcriptional factors such as TEAD1-4 to induce target  \ngene expressions, promoting cell proliferation, drug resistance, and metastasis [6] . Emerging evidence demonstrates that YAP1 upregulation of various solid cancer is positively correlated with tumor progression and poor survival outcomes [6–8] . For instance, increased YAP1 in tumors harboring BRAF V600E acts as a parallel survival factor and promote resistance to RAF and MEK inhibitor therapy [9] . YAP1 was reported to be highly upregulated in peritoneal carcinomatosis, conferring cancer stem cell properties and promoting metastasis [10, 11] . Additionally, several studies suggest that YAP1 may play a pivotal role in ovarian cancer, where elevated levels of YAP1 correlate with poor patient survival and serve as an independent pro","cbCaidZuwY7u98up","https://ap.wps.com/l/cbCaidZuwY7u98up","pdf",5195939,14,"English","# Introduction\n## YAP1 in ovarian cancer and the Hippo pathway\n## Therapeutic need and rationale\n# Study overview and mechanistic focus","[{\"question\":\"Why is YAP1 considered an appealing therapeutic target?\",\"answer\":\"YAP1 is frequently upregulated in solid cancers and contributes to tumor progression, drug resistance, metastasis, and poor survival outcomes, making it a desirable target for therapy development.\"},{\"question\":\"How does CK2α affect YAP1 in this study?\",\"answer\":\"CK2α functions upstream to regulate YAP1 turnover. Inhibiting CK2α or depleting its catalytic subunit destabilizes YAP1 and suppresses oncogenic functions in vitro and in vivo.\"},{\"question\":\"What role does DUB3 play in the CK2α–YAP1 pathway?\",\"answer\":\"DUB3 is identified as a deubiquitinase of YAP1 and functionally links CK2 to YAP1 stability. CK2α directly phosphorylates DUB3 at Thr495 to facilitate DUB3-mediated deubiquitination of YAP1.\"}]","CK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions - Article | PDF",1790169149,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecb608cedbcbf9ef34e253640796ed20.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/105f262b88a7fd8f54a55fe42f6f5bc5.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c27920119b5f98610b68169d176d5a2.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a6f4e9f11ca5d3489e23ec2350e83b7.webp",980,1301]